Related Experiment Videos

The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland

Jolanta Krzysztoń-Russjan1, Marek Gniadkowski, Hanna Połowniak-Pracka

  • 1Sera and Vaccines Central Research Laboratory, ul. Chełmska 30/34, 00-725 Warsaw, Poland.

Insights

The first vancomycin-intermediate Staphylococcus aureus (hVISA) strains in Poland were identified as the

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Clinical Science

Background:

  • Emergence of antimicrobial resistance is a global health concern.
  • Vancomycin-intermediate Staphylococcus aureus (hVISA) poses a treatment challenge.
  • Limited data exists on hVISA epidemiology in Eastern Europe.

Purpose of the Study:

  • To characterize the first identified heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) isolates in Poland.
  • To investigate the molecular relatedness and clonal origin of these hVISA isolates.
  • To determine the historical presence of the hVISA phenotype in Polish hospitals.

Main Methods:

  • Molecular typing (e.g., MLST, spa typing) was employed to analyze isolate relatedness.
  • Comparison with existing methicillin-resistant S. aureus (MRSA) isolates, including archival samples.
  • Phenotypic characterization of vancomycin susceptibility.

Main Results:

  • The identified hVISA isolates in Warsaw hospitals were closely related.
  • These isolates belonged to the international 'Iberian' methicillin-resistant S. aureus (MRSA) clone.
  • The hVISA phenotype was detected in Polish MRSA populations since at least 1998.

Conclusions:

  • The 'Iberian' MRSA clone is associated with the emergence of hVISA in Poland.
  • hVISA has been circulating in Polish hospitals for over two decades.
  • Further investigation into selection conditions and clinical impact of hVISA is warranted.

Related Concept Videos